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ABSTRACT 
Introduction  
Primary aldosteronism accounts for 6-15% of hypertension cases, the single biggest contributor 
to global morbidity and mortality. Whilst ~50% of these patients have unilateral aldosterone-
producing adenomas, only a minority of these have curative surgery as the current diagnosis of 
unilateral disease is poor. Carbon-11 radiolabelled metomidate ([
11
C]MTO) is a positron 
emission tomography (PET) radiotracer able to selectively identify CYP11B1/2 expressing 
adrenocortical lesions of the adrenal gland. However, the use of [
11
C]MTO is limited to PET 
centres equipped with on-site cyclotrons due to its short half-life of 20.4 minutes. 
Radiolabelling a fluorometomidate derivative with fluorine-18 (radioactive half life 109.8 min) 
in the para-aromatic position ([
18
F]FAMTO) has the potential to overcome this disadvantage and 
allow it to be transported to non-cyclotron-based imaging centres.  
Methods  
Two strategies for the one-step radio-synthesis of [
18
F]FAMTO were developed. [
18
F]FAMTO 
was obtained via radiofluorination via use of sulfonium salt (1) and boronic ester (2) precursors. 
[
18
F]FAMTO was evaluated in vitro by autoradiography of pig adrenal tissues and in vivo by 
determining its biodistribution in rodents. Rat plasma and urine were analysed to determine 
[
18
F]FAMTO metabolites.  
Results  
[
18
F]FAMTO is obtained from sulfonium salt (1) and boronic ester (2) precursors in 7% and 32% 
non-isolated radiochemical yield (RCY), respectively. Formulated [
18
F]FAMTO was obtained 
with >99% radiochemical and enantiomeric purity with a synthesis time of 140 minutes from the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 3 
trapping of [
18
F]fluoride ion on an anion-exchange resin (QMA cartridge). In vitro 
autoradiography of [
18
F]FAMTO demonstrated exquisite specific binding in CYP11B-rich pig 
adrenal glands. In vivo [
18
F]FAMTO rapidly accumulates in adrenal glands. Liver uptake was 
about 34% of that in the adrenals and all other organs were <12% of the adrenal uptake at 60 
minutes post injection. Metabolite analysis showed 13% unchanged [
18
F]FAMTO in blood at 10 
minutes post administration and rapid urinary excretion. In vitro assays in human blood showed 
a free fraction of 37.5%.  
Conclusions  
[
18
F]FAMTO, a new 
18
F-labelled analogue of metomidate, was successfully synthesised. In vitro 
and in vivo characterization demonstrated high selectivity towards aldosterone-producing 
enzymes (CYP11B1 and CYP11B2), supporting the potential of this radiotracer for human 
investigation.   
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1. Introduction 
 
The most common secondary cause of hypertension is primary aldosteronism (PA), which is 
reported in approximately 6-15% of all hypertensive patients. By the year 2025, PA is expected 
to directly impact one in four people with hypertension globally [1-7]. PA is characterized by an 
excess secretion of aldosterone, steroid hormone with mineralocorticoid activity produced by the 
zona glomerulosa of the adrenal cortex where aldosterone synthase (CYP11B2) enzymes play an 
essential role in aldosterone production [3, 8, 9]. Aldosterone increases sodium reabsorption and 
potassium excretion in the renal distal tubules and collecting ducts of nephrons, influencing 
water retention and blood pressure [3]. 
Therefore, pathological conditions showing an overproduction of aldosterone frequently lead 
to hypertension and hypokalaemia resulting in detrimental effects to an individual’s 
cardiovascular system [1]. Over 90% of all PA patients have a sporadic form [10]. The two most 
common subtypes of sporadic PA are unilateral aldosterone-producing adenomas (UAPA, 40%) 
or bilateral adrenal hyperplasia (BAH, 60%) [5, 11]. Correctly differentiating between the unique 
features of UAPA and BAH is crucial in identifying an appropriate intervention. UAPA is 
curable through surgical removal of the diseased adrenal whilst BAH is treated 
pharmacologically with mineralocorticoid receptor antagonists (e.g. spironolactone) [12]. The 
most significant obstacle for decision makers is the need to distinguish UAPA from other causes 
of PA such as BAH or non-functioning adrenal adenoma (incidentalomas) [13]. Invasive 
bilateral adrenal vein sampling (AVS) is the current gold-standard diagnostic procedure adopted, 
with cannulation success rates varying from 8% to 95% [10, 14-16]. 
Computed tomography (CT) and magnetic resonance imaging (MRI) have been used for non-
invasive lateralisation of aldosterone hypersecretion. These show low diagnostic accuracy due to 
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suboptimal spatial resolution and sensitivity to detect small UAPA (<1 cm) [14, 17-20]. Positron 
emission tomography (PET) is considered an accurate and non-invasive alternative to AVS in the 
management of patients with PA and adrenal adenoma [21]. 
Methyl and ethyl esters of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid, such as 
(R)-metomidate (MTO, Fig. 1) and (R)-etomidate (ETO), are a class of compounds that interact 
with the mitochondrial cytochrome P-450 enzymes (11β-hydroxylase (CYP11B1) and 
CYP11B2) in the adrenal cortex (IC50 for CYP11B1 = 0.24±0.05 nM (MTO) and 0.5±0.2 nM 
(ETO), IC50 for CYP11B2 = 0.59±0.64 nM (MTO) and 1.7±0.9 nM (ETO)) [22-24]. MTO and 
ETO have been used as template to develop PET radiolabelled radiotracers using β+-emitting 
radionuclides such as 
11
C and 
18
F [21, 25, 26]. 
Bergström et al. have developed [
11
C]MTO (Fig. 1) by radiolabelling the methyl ester group 
with 
11
C. [
11
C]MTO possesses high specific binding to adrenal enzymes in vitro and in non-
human primate studies [25, 27, 28]. Blocking experiments using ETO (10 μM) confirmed the 
specific uptake of [
11
C]MTO to pig adrenal sections [25]. In humans [
11
C]MTO showed high 
uptake in adrenal glands (SUV ratio of adrenal gland/liver ratio 1.5±0.7, 15–45 min) and high 
standardised uptake values (SUV) in aldosterone-hypersecreting adenomas [25, 27, 29-31]. 
Metabolite studies of [
11
C]MTO in humans revealed that unchanged [
11
C]MTO accounted for 
40% and 28% of total blood-borne radioactivity at 20 min and 40 min post injection, with two 
polar metabolites present in the plasma [30]. Although [
11
C]MTO has good imaging properties 
for visualization of UAPA,[21] novel radiotracers with increased adrenal-to-liver ratio (large 
liver uptake hampers the assessment of the right adrenal) and a longer half life radionuclide (e.g. 
18
F) are needed for a more widespread adoption of this diagnostic approach. 
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An increased adrenal-to-liver PET signal was achieved by adding a halogen atom (e.g. chlorine 
or bromine) in the para-position of MTO’s benzene group such as chlorine ([11C]ClMTO, Fig. 1) 
and bromine ([
11
C]BrMTO, Fig. 1). In rats [
11
C]MTO gives an adrenal-to-liver ratio of 3.8 at 30 
min post injection, increasing to 4.4 and 7.2 using [
11
C]ClMTO and [
11
C]BrMTO, respectively 
[32]. [
11
C]MTO is not used in a widespread manner, partly because of its short half-life that 
limits its use to PET centres with on-site cyclotrons. A MTO analogue with a longer fluorine-18 
half-life would enable the examination of more patients per tracer production, and its distribution 
to PET-centres without on-site cyclotrons. 
Wasdak et al. developed an ETO derivative radiolabelled with fluorine-18 ([
18
F]FETO, Fig. 1) 
to enhance the image resolution, and pharmacokinetic and pharmacodynamic properties of 
[
11
C]MTO [33]. MTO and FETO have similar binding affinities to displace the radioligand  
4-[
131
I]iodometomidate ([
131
I]IMTO) on homogenized rat adrenal membranes as an acceptable 
surrogate for testing inhibitory affinity versus CYP11B1 and CYP11B2 (IC50 = 3.69±1.92 nM 
and 2.9±0.55 nM, respectively)[34]. [
18
F]FETO was produced using an automated one-step 
protocol within 70 min (total synthesis time) with a non-isolated radiochemical yield (RCY) of 
20±3% [35]. Regional organ distribution of [
18
F]FETO in rat revealed an adrenal-to-liver ratio of 
14.48 at 60 minutes post injection [36]. Metabolite analysis indicated that [
18
F]FETO is degraded 
to 2-[
18
F]fluoroethanol in vitro and in vivo [37]. In humans, [
18
F]FETO is rapidly metabolised in 
the first 10 minutes (91% intact [
18
F]FETO after 2 minutes; 24% after 10 min, 11% after 20 min 
and 3.7% after 90 min) [37]. [
11
C]MTO and [
18
F]FETO showed rapid metabolism in vivo 
corresponding to de-esterification to the non-radioactive and inactive carboxylic acid derivative 
(IC50=0.12 mM) [34, 38] and radioactive metabolites, such as [
11
C]methanol and 
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[
11
C]formaldehyde for [
11
C]MTO and [
18
F]fluoroethanol for [
18
F]FETO, affecting the 
signal/noise ratio and specificity of the imaging data acquired [30, 36, 37]. 
A para-fluorinated aromatic (R)-MTO derivative (FAMTO, Fig. 1) has comparable affinity for 
adrenal enzymes (Ki = 7.3 nM measured using [
131
I]IMTO ) as MTO (Ki = 4.02 ± 1.87 nM) in rat 
adrenal membranes [39]. We therefore developed a radiosynthetic strategy to produce a 
18
F-
radiolabelled analogue of MTO ([
18
F]FAMTO) in order to evaluate it as a potential radiotracer 
for aldosterone-producing adenomas. 
2. Materials & Methods 
 
2.1 General Consideration 
[
18
F]Fluoride ion was produced using an RDS112 cyclotron at King’s College London PET 
Centre by the 
18
O(p,n)
18
F reaction via proton irradiation of enriched (95%) 
18
O water.  
2.2 Trapping and releasing of [18F]Fluoride ion on a Sep-Pak Accell Plus QMA cartridge  
0.5–1.5 GBq of aqueous [18F]fluoride ion was trapped in an anion-exchange resin cartridge 
(Sep-Pak Accell Plus QMA cartridge, WAT023525, Waters) pre-activated with 10 mL 1 N 
NaHCO3 (aq), 10 mL water (H2O) followed by 10 mL air. The trapped [
18
F]fluoride ion was 
released with solution A, composed of 25.5 µmol Kryptofix (K222) and 4.5 µmol KHCO3 in 
acetonitrile (MeCN): H2O (85:15, 1 mL) or solution B, composed of 19.55 µmol K222 and 0.9 
µmol K2CO3 in MeCN:H2O (85:15, 1 mL). The solvent was removed by heating at 90 °C under a 
stream of N2 and fluoride ion was dried by azeotropic distillation with MeCN (2 x 0.5 mL). 
Compound 1 (5 mg) was dissolved in anhydrous dimethyl sulfoxide (DMSO, 100-500 μL) and 
the obtained solution was added to the dried [
18
F]fluoride ion/K222/K2CO3 mixture. The vial was 
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 8 
then sealed and stirred at 110-180 °C for 15-30 minutes, quenched with H2O and analysed by 
radioTLC. 
2.3 Radioynthesis of [18F]FAMTO 
High base procedure: The trapped [
18
F]fluoride ion was released with 0.5 mL of a solution 
composed of K222 (16 µmol) and K2CO3 (2.4 µmol) in MeCN: H2O (80:20). Azeotropic drying 
was performed by addition of MeCN (2 x 0.5 mL) and heating at 90 °C under a stream of N2. To 
the dried mixture, 500 µL of DMF was added. Aliquots of 500, 250, 125 and 87 µL of 
[
18
F]KF/K222/K2CO3, 2 (6.3 mg, 18 µmol) and tetrakis(pyridine)copper(II) triflate 
(Cu(OTf)2(py)4, 3.6 mg, 5 µmol) were added in a vial. DMF was added to achieve a final volume 
of 500 µL (see Table 2). Radiofluorination was conducted at 118 °C for 20 min, cooled to room 
temperature, and diluted with H2O. 
Low base procedure: Aqueous [
18
F]fluoride ion (100-1000 MBq) was loaded onto a QMA 
cartridge, the cartridge was flushed with air and the 
18
F elution was performed using 2 mL of 
K222 (1.5 µmol) and K2CO3 (0.87 µmol) in MeCN: H2O (80:20). Azeotropic drying was 
performed by addition of MeCN (2 x 1 mL) and heating at 90 °C under a stream of N2. To the 
dried mixture DMF (500, 300, 200, and 100 µL), 2 (6.3 mg, 18 µmol) and Cu(OTf)2(py)4 (3.6 
mg, 5 µmol) were added (see Table 2). Radiofluorination was conducted at 118 °C for 20 min 
under air, cooled to room temperature, and diluted with H2O. 
2.4 Purification and Analysis of [18F]FAMTO 
The crude mixture was purified by semi-preparative HPLC (see Appendix A). The purified 
[
18
F]FAMTO was subsequently diluted with 40 mL of PBS, the solution loaded onto a Sep-Pak 
tC18 Plus Long SPE Cartridge 900 mg, 37-55 µm (cat. no. WAT036800, Waters) and eluted 
with ethanol (2 mL). Ten fractions (0.2 mL) were collected and radioactivity determined. 
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 9 
Fractions with highest radioactivity were combined and formulated with saline. The formulated 
solution (4-6 mL of 10% ethanol in saline) containing 1-10 MBq of [
18
F]FAMTO was used for in 
vitro and in vivo experiments. Analytical reverse-phase HPLC (see Appendix A) was used to 
determine the molar activity, radiochemical and chemical purity. Identification of the radioactive 
products was confirmed by co-elution of added non-radioactive compounds.  
2.5 Determination of chiral conformation and enantiomeric excess of 2,4 and [18F]FAMTO 
Circular dichroism (CD) spectra of (R)-ETO (enantiomeric excess (e.e.) > 99%, Sigma 
Aldrich), (R)-2, (R)-4 and (S)-8 (e.e. > 97%, Sigma Aldrich) were acquired on the Applied 
Photophysics Ltd Chirascan Plus spectrometer (Fig. S1). 
Enantiomeric purity of (R)-2, (R)-4, (R)-5, and (R)-[
18
F]FAMTO was performed on a chiral 
HPLC Lux 5 µm Cellulose-3 250 x 4.6 mm coloumn (Table S2). Commercial (R)-ETO (e.e. > 
99%) and (S)-8 (e.e. > 97%) were used as control. 
2.6 Determination of RCY and molar activity of [18F]FAMTO 
The entire quenched reaction mixture was used to determine non-isolated and isolated RCY. 
All RCYs are reported as decay corrected values [40]. Non-isolated RCYs were determined by 
integrating the area under the curve in the preparative radio-HPLC chromatogram or iTLC. 
Isolated RCY were calculated by relating the amount of isolated [
18
F]FAMTO to the amount of 
[
18
F]fluoride ion trapped on QMA cartridge. 
The molar activities (GBq/µmol) were calculated by dividing the radioactivity of [
18
F]FAMTO 
by the amount of the unlabeled FAMTO determined from the peak area in the UV-HPLC 
chromatograms (λ= 254 nm, common wavelength for identifying metomidate derivative 
compounds such as etomidate and iodometomidate [25, 38], fig. S1). FAMTO concentrations 
were determined from a UV-absorbance calibration curve (see Appendix A).  
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2.7 Pig Organ Tissues 
Pig tissues were purchased from Seralab, UK. Adrenal glands, kidneys, and liver were 
collected from an healthy animal (female, 9 months old). Tissues were delivered at 4 °C in 
Dulbecco’s media. Once collected, tissues were cut in small and medium pieces. Pieces were 
snap frozen in an isopentane bath cooled to -30 °C and stored at -80 °C. 
2.8 Autoradiography 
Frozen sections (20 μm) of pig adrenal glands, kidneys, and liver were prepared in a Cryostat 
and put on superfrost glass slides. At the start of the experiment, the slides warmed to room 
temperature and preincubated for 10 min in TRIS buffer (50 mM, pH 7.4). Slides were then 
transferred to containers containing 1 nM of [
18
F]FAMTO in 40 mL of TRIS buffer (50 mM, pH 
7.4). In a duplicate set of containers, 1 μM of MTO was added to block specific binding. After 
incubation for 30 minutes (the slides were washed 2×3 min in fresh 50 mM TRIS buffer, pH 
7.4). The slides were dried and then exposed to phosphor imaging plates (BAS-IP TR 2040, GE 
Healthcare, UK) for 30 minutes and scanned in a Typhoon 8600 phosphorimager (GE 
Healthcare, UK). Images (Fig. 2) were analysed using OptiQuant 5.0 software (PerkinElmer, 
UK). 
2.9 Animal Studies 
Biodistribution and metabolite studies were carried out in adult male Sprague-Dawley rats 
(300–400 g). All animal studies were carried out in accordance with the UK Home Office 
Animals (Scientific Procedures) Act 1986. Experiments complied with UK Research Councils’ 
and Medical Research Charities’ guidelines on responsibility in the use of animals in bioscience 
research, under UK Home Office project and personal licenses. 
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2.10 Ex Vivo Biodistribution  
Nine anesthetized rats (2–3% isoflurane/oxygen) were injected intravenously with 1-3 MBq/kg 
of formulated [
18
F]FAMTO and sacrificed at 15, 30 and 60 minutes post-injection. The specific 
uptake of [
18
F]FAMTO was evaluated in three anesthetized rats (2–3% isoflurane/oxygen) using 
1 mg/kg ETO i.v. (95% saline and 5% ethanol) 15 minutes before [
18
F]FAMTO injection (1-3 
MBq/kg), and animals sacrificed 30 minutes post radiotracer injection. Tissues including whole 
brain, heart, lungs, stomach, liver, spleen, small intestine, large intestine, kidneys, bladder, thigh 
bone, adrenal glands, and testes were excised. Urine and blood were also collected. All samples 
were weighed and radioactivity content measured using an automated well counter with a 
standard dilution of [
18
F]FAMTO. Counts were decay-corrected and the %ID/g calculated (Fig. 
3A and Table S1). Data are expressed as mean ± standard error (SE) from three independent 
replicates, unless otherwise indicated. Statistical analysis of %ID/g in the biodistribution study 
was performed with IBM SPSS Statistics (version 24). Student t-tests were used to determine 
statistical significance with P < 0.05 considered significant. 
2.11 Analysis of Radiolabelled Metabolites in Rats 
Blood and urine samples were collected at 10, 30, and 60 minutes post injection to measure the 
amounts of unchanged tracer and radioactive metabolites. Blood was centrifuged at 6000 rpm for 
5 min, the supernatant was treated with MeCN (1:1) and centrifuged to precipitate plasma 
proteins. Plasma supernatant and urine samples were then injected into an HPLC semipreparative 
column (see Appendix A), and the eluate collected in 1.5 mL test tubes and gamma-counted. 
Two metabolites (tR = 3 and 21 minutes) and [
18
F]FAMTO were observed in the plasma (Fig. 4). 
One metabolite (tR = 3 minutes) was observed in the urine (Fig. S2). 2.5 μL aliquots of 
radioactivity eluting at tR = 3 minutes and compound 12 (Scheme 1) were analysed by TLC 
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plates (Merck F-254 silica gel) eluted with dichloromethane:methanol:trifluoroacetic acid (TFA) 
(8:2:0.05). TLC plates were scanned in a Typhoon 8600 phosphorimager (GE Healthcare, UK) 
and analysed using OptiQuant 5.0 software (PerkinElmer, UK). 
2.12 Stability Studies in Plasma 
Human blood (1 mL) was incubated with 0.7-1 MBq (200 µL) [
18
F]FAMTO at room 
temperature for 10 and 20 minutes. After incubation, plasma was separated by centrifugation (5 
min, 4000×g) and the proteins were precipitated by the addition of an equal volume of MeCN. 
The tubes were centrifuged for 5 min at 4000×g. The supernatant was then injected onto the 
HPLC (HPLC method 1) and serial 1.5 mL HPLC fractions were collected and gamma-counted. 
[
18
F]FAMTO (0.7-1 MBq, 200 µL) incubated in PBS (1 mL) was used as control. 
2.13 Plasma Protein Binding 
The plasma protein binding of [
18
F]FAMTO was measured in the plasma of blood samples. 
Plasma was prepared from fresh human blood by centrifugation (5 min, 4000×g) at room 
temperature. Two vials containing fresh human plasma (300 µL) and PBS (300 µL, control) were 
incubated at room temperature with 30 µL of a solution containing [
18
F]FAMTO (1-2 MBq). 
After 10 minutes, each solution was sampled and counted. The solution (200 µL) was injected 
into a filter device (Millipore Centrifree tubes, YM-30) and subsequently centrifuged for 5 
minutes at 6000 rpm. The solution passed through a centrifugal filters unit (nominal molecular 
weight limit 30,000 Dalton) and the filtrate and control samples were gamma-counted. 
2.14 PET Imaging 
PET-CT scans were performed on a BioScan nanoPET-CT
® 
PLUS (Mediso, Hungary) scanner 
using their proprietary acquisition software (Nucline 1.07). The rats were anaesthetised and 
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maintained at 2.5% isofluorane and 1 L/min flow of Oxygen (O2). A CT scan was acquired prior 
to the commencement of the PET scan. Dynamic PET scans were acquired for 60 minutes post 
intra-venous (IV) administration by tail vein injection of [
18
F]FAMTO (1.0 MBq, n=2) or by pre-
administration ETO (1 mg/Kg) 15 minutes prior to [
18
F]FAMTO injection (1.0 MBq, n=1). 
PET scans were reconstructed using Tera-Tomo 3D image reconstruction algorithm. 
Reconstructions were performed with the detector coincidence mode set at 1:3. Corrections for 
decay, randoms, crystal dead time, detector normalization and, attenuation correction was 
implemented. A total of 6 subsets and 4 iterations were applied resulting in a voxel size of 
0.25×0.25×0.25 mm
3
 for CT, and 0.4×0.4×0.4 mm
3
 for PET. The PET and CT images were co-
registered automatically. Image analysis was performed using pre-clinical image post processing 
software VivoQuant
TM
. 
 
3. Results  
 
3.1 Chemistry 
Aryl sulfonium salt 1 (Scheme 1) was synthesised following the procedure reported by Sander et al. 
[41]. The thioether 5 reacted with diaryliodonium triflate under copper(II) catalysis (125 °C, 1 h) 
giving 1 in 53% yield. Pinacol boronate ester 2 was prepared by the following procedure adapted from 
the literature [42]. The para-bromo MTO derivative (6) reacted with bis(pinacolato)diboron in the 
presence of potassium acetate and Pd-catalyst to form 2 with a yield of 76±10% (n=3).  
Scheme 1 shows the route used to synthesize 3-6 via Mitsunobu reaction that involves the use of both 
an oxidising agent such as di-tert-butyl azodicarboxylate (DtBad) and a reducing agent such as 
triphenylphosphine (PPh3) under mild conditions. Yields between 40-60% were obtained.  
3.2 Radiosynthesis of [18F]FAMTO  
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Two 
18
F-labeling strategies were selected to produce [
18
F]FAMTO, the first via an aryl 
sulfonium salt (1, Scheme 1) and the second via an aryl boronic precursor (2).  
The strategy of labeling sulfonium salts with 
18
F fluoride ion has been reported to be a direct, 
straightforward nucleophilic substitution [41]. Following the optimised procedure developed by 
Sander et al., dimethyl sulfoxide (DMSO), potassium bicarbonate (KHCO3, 30 mM), Kryptofix (K222, 
30 mM) and 1 (5 mg) in 500 μL DMSO at 110 °C for 15 minutes, [18F]FAMTO was obtained with 
very low non-isolated radiochemical yield (RCY, 1%, entry 1, Table 1). 
Screening of solvent volume, time and bases commonly used for nucleophilic substitution reactions 
with [
18
F]fluoride ion was investigated in an attempt to improve the RCY. Increasing the 
concentration of precursor from 0.01 mg/mL to 0.02 mg/mL (entry 2) or increasing the reaction time 
from 15 to 30 minutes (entry 3) did not give the desired product. By substituting KHCO3 with K2CO3, 
[
18F]FAMTO was obtained using 500 and 250 μL of DMSO with a non-isolated RCY of 8% and 7%, 
respectively (entries 4-5). Decreasing further the volume of DMSO to 100 μL caused a RCY drop 
(entry 6). Increasing the temperature from 110 to 150 or 180 °C, afforded no [
18
F]FAMTO 
whatsoever. 
An alternative radiolabelling strategy to produce [
18
F]FAMTO was subsequently investigated 
starting from the aryl boronic derivative 2. Initially, the experiment was performed by mixing a 
solution of 2 and Cu(OTf)2(py)4 in DMF with the dried residue of [
18
F]fluoride ion/K222/K2CO3 and 
heated at 110 °C for 20 min under air. The formation of [
18
F]FAMTO under these conditions was not 
observed (entry 1, Table 2).  
Neumaier and coworkers have reported an efficient protocol to increase the RCY of copper-
mediated aromatic radiofluorination using a “low amount of base” strategy [43]. Indeed using small 
amount of K222/K2CO3 in DMF obtained by aliquoting the dried residue of [
18
F]fluoride 
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ion/K222/K2CO3 (K222= 10 μmol and K2CO3 = 6 μmol), a selective 
18
F-incorporation was observed 
affording [
18
F]FAMTO with a non-isolated RCY of 17% (entry 2, Table 2). As the “low base” 
approach gave promising results, we further reduced the amount of K222 and K2CO3 present in the 
reaction solution. Decreasing 2- and 4-times the amount of K222 and K2CO3, [
18
F]FAMTO was 
produced with a RCY between 16-23% (entries 3-4, Table 2). 
Subsequent experiments were performed using the same amount of K2CO3 and K222 for 
[
18
F]fluoride ion elution and radiofluorination reaction allowing an easy transferability of manual 
procedures to automated synthesis modules. [
18
F]Fluoride ion was eluted from an anion 
exchange resin with a solution of K2CO3 (0.87 μmol) and K222 (1.5 μmol) dissolved in 
MeCN:H2O. Following the solvent evaporation, a solution of Cu(OTf)2(py)4 and 2 in 500 µL 
DMF was added to the dried residue of [
18
F]fluoride ion/K222/K2CO3 and the reaction mixture 
heated at 110 °C for 20 minutes. [
18
F]FAMTO was produced with non-isolated RCY of 32 ± 6% 
(entry 5). We next optimized the reaction with respect to solvent volume. Decreasing the volume 
of DMF from 500 to 300 and 200 µL (entries 6-7), the RCY of [
18
F]FAMTO remained the 
same. However a further decrease of the volume to 150 µL (entry 8), resulted in a non-isolated 
RCY drop from 32% to 11%. The synthesis, purification/reformulation and quality control time 
for the preparation of [
18
F]FAMTO are 75, 25 and 20 minutes, respectively. The radiosynthesis 
of [
18
F]FAMTO was achieved with an overall decay-corrected RCY of isolated [
18
F]FAMTO of 
18 ± 2%, >99% RCP, >99% e.e. and 105 ± 39 GBq/µmol molar activity within 120 minutes of 
work, starting from 850-734 MBq of 
18
F-fluoride. 
 
3.3 In vitro autoradiography 
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The in vitro binding of [
18
F]FAMTO was evaluated by autoradiography using pig adrenal, kidney 
and liver tissues. The incubation of adrenal gland sections with [
18
F]FAMTO showed a high specific 
binding with the signal of [
18F]FAMTO completely blocked with 1 μM of MTO. Both liver and 
kidney organ samples were selected due to their known role in [
11
C]MTO metabolism and excretion 
[25]. Blocking studies revealed a high specific binding in the liver and kidney, organs known to be 
rich in cytochrome P450 enzymes. 
3.4 Ex Vivo Biodistribution, metabolite analysis and in vivo PET Imaging Studies in Rats 
Ex vivo biodistribution data (Fig. 3A and Table S1), performed in healthy Sprague-Dawley rats, 
was used to assess the adrenal uptake as well as the adrenal-to-organ ratio. [
18
F]FAMTO showed high 
liver uptake in the first 10 minutes (%ID/g = 3.61 ± 1.53) followed by a slight decrease at 30 min 
(%ID/g = 2.16 ± 1.53) and 60 min (%ID/g = 1.68 ± 0.18). Adrenal uptake increased slowly during the 
first 30 minutes up to %ID/g = 6.2 ± 0.46, followed by a slow decrease up to %ID/g = 4.92 ± 0.70 at 
60 minutes. Adrenal-to-liver ratio increased from 0.66 at 10 minutes to 2.8 at 30 minutes post-
injection (Fig. 3A and Table S1).  
Rats that received ETO (1 mg/kg) 10 minutes prior to injection of [
18
F]FAMTO showed a 
significant decrease in liver uptake (66%, p = 0.005, see Table S1) and a moderate decrease in the 
adrenal glands (39%, p = 0.03). Pre-treatment with ETO increased the ratio of %ID/g in adrenal to 
liver by 38% (p = 0.12) leading to an enhanced adrenal-to-liver PET signal compared to the non-pre-
treatment group. n in vivo PET image of the adrenal uptake of [
18
F]FAMTO after  pre-treatment 
with ETO (1 mg/kg) is shown in Fig. 3B and S4.  
Plasma metabolite analysis revealed 13%, 8% and 2% of unchanged [
18
F]FAMTO at 10, 30 and 60 
minutes post-injection, respectively. Two hydrophilic metabolites at retention times 3 and 21 minutes 
were observed (Fig. 4). The metabolite eluting at 3 minutes has been identified as the free acid [
18
F]12 
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(Fig. S3). Urine metabolite analysis revealed only one metabolite in solution corresponding to [
18
F]12 
(Fig. S2). 
 
3.5 Stability Studies in Human Blood And Plasma Free Fraction 
Plasma-derived metabolites can cause a non-specific signal that reduces the specificity and quality 
of PET imaging endpoints. Metabolite studies of [
11
C]MTO or [
18
F]FETO in humans revealed that 
unchanged radiotracer accounted for 40% and 11% of total blood-borne radioactivity at 20 min 
post injection, respectively and, considering the rapid in vivo metabolism of both radiotracers 
[30, 37], we decided to perform [
18
F]FAMTO metabolite studies over a similar (20 minutes) 
timeframe for comparison. No degradation of [
18
F]FAMTO was observed after incubation in 
human blood for 20 minutes. The plasma free fraction of [
18
F]FAMTO was determined to be 
37.55 ± 5.78% (mean ± SD, n=5) by ultrafiltration. 
 
4. Discussion 
The development of the novel 
18
F radiotracer targeting adrenal gland enzymes represents a valuable 
advancement to the field of PA PET imaging. Our PET radiotracer development approach started 
from the structure-activity relationship analysis of MTO (Ki = 4.02 ± 1.87 nM), a potent inhibitor of 
CYP11B1 and CYP11B2 adrenal gland enzymes, and its derivatives bearing a halogen atom on the 
benzene ring (e.g. Br, I and F). [
11
C]MTO is a prototype radiotracer offering a rapid non-invasive 
procedure localizing aldosterone-producing adenomas [21, 44]. MTO derivatives bearing an 
iodine, bromine or fluorine atom in the 4-position of the benzene ring (Ki = 8.7 ± 3.2 nM, 8.8 ± 2.4 
nM and 8.15 ± 0.85 nM, respectively) have similar inhibitory activity to MTO, indicating that 
structural modification on the benzene ring does not significantly impact the affinity to the target’s 
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binding pocket [24, 34, 39]. These results encouraged us to attach a fluorine-18 atom at para-position 
of the MTO benzene ring generating a novel PET radiotracer ([
18
F]FAMTO, Fig. 1).  
Initial investigations, focused on using previously recognised strategies to incorporate fluorine-18 
into aromatic rings in a one-step reaction using synthetically accessible precursors such as aryl 
sulfonium salt 1 or an aryl boronic precursor 2 to obtain the R-enantiomer of [
18
F]FAMTO. The R-
configuration of MTO (IC50= 3.69 ± 1.92 nM) is a 130 times more potent an inhibitor than its S-
enantiomer (IC50= 492 ± 281 nM) [34]. 
Using the aryl sulfonium strategy, a benzylic 1H-imidazole derivative, ETO fragment, has been 
radiolabelled by Sander et al. in 31% RCY [41]. Applying the same conditions to 1, the production of 
[
18
F]FAMTO was not achieved. Following a procedure developed by Mu et al. [45] that uses K2CO3 
instead of KHCO3 and lowering the base concentration from 15 to 6 μmol, [
18
F]FAMTO was obtained 
in low non-isolated RCY (7 ± 2 %).  
An alternative radiolabelling strategy to produce [
18
F]FAMTO was subsequently investigated 
starting from the aryl boronic derivative 2. When the dried residue of [
18
F]fluoride ion/K222/K2CO3 is 
taken up in a solution in DMF in the presence of copper-catalyst and 2, the 
18
F-incorporation was not 
observed. A similar trend was observed by Neumaier et al. who demonstrated that large quantities of 
K2CO3 to elute [
18
F]fluoride ion from ion exchange cartridges impacts negatively on copper-mediated 
radiofluorination reactions, decreasing the RCY of the desired radiotracer [43]. Indeed using small 
aliquots of K222/K2CO3 in DMF obtained by dissolving the dried residue of [
18
F]fluoride 
ion/K222/K2CO3, a selective 
18
F-incorporation was observed affording [
18
F]FAMTO with an overall 
decay-corrected RCY of isolated [
18
F]FAMTO of 18%. 
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In vitro autoradiography on pig adrenal, liver and kidney sections, initially used to characterise the 
binding properties of [
18
F]FAMTO, demonstrated that [
18
F]FAMTO bound specifically to adrenal 
gland enzymes and that binding was completely blocked using 1 μM of MTO. 
The simplicity of radiolabelling and encouraging results from in vitro studies justified further 
evaluation of the new tracer in vivo. Clinically desirable features for a PET radiotracer to be used in 
the identification of adenomas include high and specific radioactivity concentration in adrenal glands, 
rapid renal excretion, and low non-specific uptake of [
18
F]FAMTO in non-target tissues (e.g. liver, 
bone).  
In vivo studies confirmed the high specificity of [
18
F]FAMTO uptake in adrenal glands showing a 
ratio of adrenal-liver uptake of 2.81 at 30 minutes post injection, which is similar to the adrenal 
gland-to-liver ratio of [
11
C]MTO in rats (3.8 at 30 min) [46]. This ratio would be expected to be 
elevated in the presence of UAPA due to an overexpression of adrenal enzymes [8, 47]. 
Image analysis of the rats administered with [
18
F]FAMTO was hampered by the high liver uptake 
masking the signal of the right adrenal gland. The pre-treatment of ETO 15 minutes prior to 
[
18
F]FAMTO injection lowered the liver uptake and increased the signal adrenal gland-to-liver of 
[
18
F]FAMTO (Fig. 3B and S4). Because of the known rapid metabolism of ETO in vivo [48-50], it is 
not expected that pre-treatment with 1 mg/kg ETO will cause complete blockade. However, in vitro, 
in the absence of MTO metabolism, 1 μM MTO was sufficient to fully block [18F]FAMTO specific 
binding. 
High radioactivity was observed in the urine (urine-blood ratio was 4.36, 24.9 and 49.1 at 10, 30 
and 60 minutes, respectively). Conversely, no uptake was visualised in bone, indicating an absence of 
[
18
F]FAMTO defluorination. 
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A metabolite study collecting rat blood samples after [
18
F]FAMTO injection revealed that 13% of 
radioactivity after 10 minutes was due to [
18
F]FAMTO (Fig. 4). The main metabolite in plasma and 
urine was identified to be the carboxylic acid of [
18
F]FAMTO ([
18
F]12, Fig. 4, Fig. S2 and S3). In 
analogy to the carboxylic acid derivative of MTO, we anticipate that compound 12 would also 
have negligible affinity for adrenal gland enzymes [34].Low metabolic stability of MTO and 
FETO has been observed in vitro and in vivo [30, 37]. However, in humans [
18
F]FETO is 
metabolised faster than [
11
C]MTO. At 20 minutes post injection, the unchanged [
18
F]FETO is 
11% whereas [
11
C]MTO is 40% of total radioactivity [30, 37]. The methyl-ester [
18
F]FAMTO 
might have the same profile as [
11
C]MTO, rather then the ethyl-ester [
18
F]FETO, however this 
hypothesis needs to be confirmed by determining [
18
F]FAMTO radiometabolic profile in 
humans. Blood-borne esterases might also produce radiometabolites to generate a non-specific 
background signal, reducing the specificity and quality of PET imaging endpoints. Because of 
this the stability of [
18
F]FAMTO was evaluated in human plasma revealing that [
18
F]FAMTO is 
highly stable in human plasma and blood. 
 
5. CONCLUSION 
 
[
18
F]FAMTO, a new 
18
F-labelled analogue of (R)-MTO was synthesized in a one-step 
radiofluorination procedure in good yields. The method utilises a synthetically accessible boronic 
ester precursor 2, produced in a one-step reaction. A low base protocol is crucial for successful 
[
18
F]FAMTO labelling. In vitro and in vivo experiments have shown that [
18
F]FAMTO 
accumulates in adrenal glands, with good adrenal-to-liver ratios in rodents and a good 
radiometabolic profile with slow kinetics in the adrenals and rapid kinetics in the liver. The 
simplicity of radiolabelling and encouraging preclinical results justify progression to toxicology 
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safety assessment studies and translation of [
18
F]FAMTO to healthy volunteers and patients with 
adrenal lesions of different adrenocortical and non-adrenocortical origin. 
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Fig. 1. Chemical structures of ETO, MTO, [
11
C]MTO, [
11
C]BrMTO, [
11
C]ClMTO, [
18
F]FETO, 
and [
18
F]FAMTO.   
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Fig. 2. Frozen tissue-section autoradiography of [
18
F]FAMTO (1 nM) binding to pig adrenal, pig 
liver, pig kidney. Lower panel [
18
F]FAMTO (1 nM) blocking studies using 1 μM MTO.   
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Fig. 3. (A) Organ uptake of [
18
F]FAMTO (i.v.) in male Sprague Dawley rats (n=3, for each 
group) at 10, 30, 60 minutes post injection. Rats pre-treated with ETO (1 mg/Kg, i.v.) 15 min 
prior to [
18
F]FAMTO i.v. injection and culled after 30 minutes. A two-tailed paired Student’s t 
test was used to compare adrenal-liver uptake and adrenal uptake in rats pre-treated with ETO 
versus that of control rats. (B) In vivo PET imaging of a male Sprague Dawley rats showing 
adrenal uptake of [
18
F]FAMTO after pre-treatment with ETO (1 mg/kg).   
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Fig. 4. Plasma metabolite analysis of [
18
F]FAMTO in male Sprague Dawley rats at 10, 30, 60 
minutes post radiotracer injection.  
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Scheme 1. Reaction scheme for production of MTO, FAMTO, 12, and [
18
F]FAMTO. a: DtBAD, 
PPh3, THF, 0 °C, rt, 17 h; b: Ph2ITfO, Cu(C6H5COO)2 TFSA, PhCl, 125°C, 2 h; c: (BPin)2, 
KOAc, (C17H14P)2Fe · PdCl2, DMSO, 80 °C, 15 h; d: [
18
F]fluoride ion, DMSO, 110 °C, 14-30 
min; e: [
18
F]fluoride ion, Cu(Py)4(OTf)2, DMF, 110 °C, 20 min; f: NaOH 2N, MeOH, rt, 17 h. 
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Table 1. Radiosynthesis of [
18
F]FAMTO from 1.  
Entry Releasing solution Time (min) Volume (mL) Temperature (°C) Non-isolated RCY (%)
c
 
1 A
a
 15 500 110 1 ± 0.5 (n=3) 
2 A 15 250 110 0 (n=2) 
3 A 30 250 110 0 (n=2) 
4 B
b
 30 500 110 8 (n=1) 
5 B 30 250 110 7 ± 2 (n=3) 
6 B 30 100 110 1, 4 (n=2) 
7 B 30 250 150 0 (n=1) 
8 B 30 250 180 0 (n=1) 
a
Solution A: 0.5 mL K222 (30 mM) and KHCO3 (30 mM) in MeCN:H2O (85:15).  
b
Solution B: 1 mL of K222 (23 mM) and K2CO3 (6 mM) in MeCN:H2O (85:15). 
c
Determined by radio-TLC (% ± SEM). 
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Table 2. Optimization of radiofluorination of 2 to form [
18
F]FAMTO. 
 Releasing solution  Reaction   
Entry
a
 K222 
(μmol) 
K2CO3 
(μmol) 
Activity 
released 
from QMA 
(%) 
K222 
(μmol) 
K2CO3 
(μmol) 
Volume 
(DMF) Non-isolated 
RCY (%)
b
 
Isolated 
RCY (%)
c
 
1 20 12 
95 ± 4 
(n=8) 
20 12 500 0 (n=2) n.d. 
2 20 12 10 6 500 17, 16 (n=2) n.d. 
3 20 12 5 3 500 18, 16 (n=2) n.d. 
4 20 12 3 1.5 500 22, 23 (n=2) n.d. 
5 1.5 0.87 
82 ± 2  
(n= 27) 
1.5 0.87 500 32 ± 6 (n=5) 28 ±14 (n=5) 
6 1.5 0.87 1.5 0.87 300 29 ± 7 (n=3) n.d. 
7 1.5 0.87 0.87 200 200 32 ± 2 (n=18) 18 ± 2 (n=18) 
8 1.5 0.87 0.87 150 150 11 (n=1) n.d. 
 
a 
2 (18 µmol), Cu(OTf)2(py)4 (5 µmol), DMF (150-500 uL), 20 min, 110 
o
C. 
b
Estimated by analytical radio-HPLC of the crude product (% ± SEM). 
c
Calculated from the amount of isolated [
18
F]FAMTO to the initial amount of [
18
F]fluoride ion 
trapped in the Sep-Pak Accell Plus QMA cartridge (% ± SEM). 
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Appendix A. Supplementary data 
The following is the Supplementary data to this article.  
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